More than $15 billion of capital was accessed by Indiana’s life sciences companies in 2021. BioCrossroads today issued their annual report, Indiana Life Sciences Capital 2021, which provides details on the funding events throughout the year, including:

  • $6.5 million in Small Business Innovation Research (SBIR) awards to 17 companies
  • A record $433.5 million in Venture Capital invested in 39 companies
  • $508 million accessed through public markets by four companies
  • $13.7 billion+ spent to acquire innovation representing 13 transactions
  • $521 million in capital to establish, expand, or upgrade facilities by 23 companies
Download PDF
BioCrossroads Life Sciences Capital Report 2021